Search Results - ovarian+cancer

10 Results Sort By:
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU 2025-212 IP...
Published: 4/29/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
Anti-CD73 Monoclonal Antibody for Enhanced Cancer Immunotherapy
NU 2020-207 INVENTORS Bin Zhang* Siqi Chen Jie Fan SHORT DESCRIPTION This invention comprises novel anti-CD73 monoclonal antibody compositions that recognize and inhibit mouse and human CD73. BACKGROUND CD73, an ecto-enzyme associated with adenosine metabolism, is an emerging immune checkpoint that promotes tumor progression by suppressing...
Published: 12/11/2025   |   Updated: 1/30/2025   |   Inventor(s):  
Keywords(s): Brain cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Immunotherapy, Lung cancer, Ovarian cancer, Pancreatic cancer, Therapeutics
Category(s): Life Sciences > Therapeutics
Advancement in Platinum Based Cancer Therapeutics
One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells. Although increased DNA repair has been shown to be a major mechanism of cancer drug resistance, not much was done until recently to address this challenge. The researchers at The University of Toledo have discovered small drug like molecules...
Published: 4/16/2026   |   Updated: 1/2/2025   |   Inventor(s): Stephan Patrick, Paul Erhardt
Keywords(s): Cisplatin, Clinical Trials, DNA Repair, Ovarian Cancer, Platinum
Category(s): Oncology
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Summary: The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies. Description of Technology: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li
Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Metastatic ovarian cancer mouse models and cell lines for preclinical studies
Abstract: The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs at a high rate. One of the rate limiting factors...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Simone Difilippantonio, Terry Van Dyke, Ludmila Szabova, Chaoying Yin, Yurong Song
Keywords(s): GDA, GEM Derived Allograft Mouse Model, Genetically Engineered Mouse (GEM) Model, OVARIAN CANCER, SEOC, Serous Epithelial Ovarian Cancer
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials
Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines
Description of Technology: Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Stuart Aaronson, Nelson Ellmore (Estate)
Keywords(s): A2780, Aaronson, adriamycin, CISPLATIN, drug resistance, IRRADIATION, Melphalan, OVARIAN CANCER, VINBLASTINE
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials
Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES
Summary: NCI is seeking parties to non-exclusively license the ADR-RES cell line. Description of Technology: Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Kenneth Cowan
Keywords(s): ADENOCARCINOMA, Adriamycin-resistant, Cell line, Cowan, MCF-7/ADR-RES, MDR1, Multi-Drug Resistance, NCI/ADR-RES, OVARIAN CANCER, OVCAR-8, P-GLYCOPROTEIN
Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Oncology
Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN
PTEN is a tumor suppressor gene that is frequently deleted or mutated in a variety of human cancers, including prostate, breast, endometrial, lung, and ovarian cancers. In prostate cancer cells, PTEN deletion is the most common event observed. The loss of PTEN is thought to play and important role in tumor cell proliferation and metastasis due to...
Published: 5/7/2025   |   Updated: 12/6/2022   |   Inventor(s): Michael Quon, Derek Leroith
Keywords(s): ADENOCARCINOMA, BREAST CANCER, CA1XXX, CANCER, CAXXXX, CCXXXX, Cells, CHARACTERIZATION, Chromosome 7, monosomy, CXXXXX, Deletion 7, endometrial, Expressing, Gene, IGF1R, lung cancer, MEN 1, OVARIAN CANCER, PROSTATE CANCER, PTEN, tumor suppressor, Zollinger-Ellison syndrome
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials
Biomarkers for Early Detection of Serous Ovarian Cancer
Ovarian cancer is one of the most common cancers among women, with over 21,000 new cases and over 14,000 deaths per year. If detected early, the 5-year survival rate is over 80%, but that drops to just 11% if detected at stage IV, and over 60% of patients are diagnosed with advanced disease. Early detection is hampered by limitations in current biomarkers,...
Published: 2/26/2026   |   Updated: 11/11/2020   |   Inventor(s): Benjamin Katchman, Karen Anderson, Garrick Wallstrom, Joshua LaBaer, Daniel Cramer
Keywords(s): Antibodies, Autoantibody, Biomarker discovery, Cancer, Diagnostics, Early Detection, Immunosignature, Ovarian Cancer
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Medical Diagnostics/Sensors, Proteomic Assays/Reagents/Tools
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2014-33Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells....
Published: 6/18/2024   |   Updated: 8/19/2014   |   Inventor(s): Paul Erhardt, Stephan Patrick, Christopher Trabbic
Keywords(s): Cisplatin, Clinical Trials, DNA Repair, Ovarian Cancer, Platinum
Category(s): Oncology, Tools